Compare Amphastar Pharmaceuticals Inc (AMPH) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs SkyWest Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while SkyWest Inc trades at $99.72 (market cap $3.96B). The key difference: SkyWest Inc is far larger — about 4.8× Amphastar Pharmaceuticals Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SKYW | |
|---|---|---|
Market Cap | $826.08M | $3.96B |
Sector | Health | Technology |
52-Week High | $30.81 | $123.72 |
52-Week Low | $16.87 | $78.40 |
Enterprise Value | $1.22B | $5.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SkyWest (SKYW) trades at $99.72, down 0.29% on the day, with strong technical momentum showing bullish moving averages and key support at $98. The company maintains solid fundamentals with a P/E of 9.57, net income margin of 10.42%, and consistent earnings beats in recent quarters. Recent leadership changes include Wade Steel's promotion to President and COO of SkyWest Airlines.
SkyWest presents attractive valuation with upside to the $109.33 consensus price target, supported by strong analyst sentiment (56% buy ratings). Key risks include rising fuel costs highlighted in recent government data showing 84% year-over-year increases, which could pressure airline profitability despite current operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
